TP53 and cancer: found that the oncogenic p53 variations R273 (R273H, R273C, and R273L) not only lose their DNA-binding capabilities but also have different structural stability, aggregation, and toxicity profiles and lead to different types of cancer pathogenesis in vivo (63).